US Wrangler partners with Genesco in multiyear footwear licensing deal
The agreement between Wrangler and Genesco is a strategic move for both companies, designed to support Wrangler's growth and development as a cross-category lifestyle brand and leverage and build on Genesco's extensive branded footwear expertise. Wrangler seeks to expand its reach and accessibility, resonating with a broader audience looking for style and functionality across both apparel and footwear.
The initial collection will feature a blend of classic Wrangler inspired designs and more trend-driven styles. With Wrangler's signature rugged look and Genesco's track record for innovation and success, the partnership promises to deliver fresh and distinctive designs to the market.
Wrangler has signed a multiyear licensing deal with Genesco to design, source and market footwear for men, women and children. The partnership aims to expand Wrangler's lifestyle brand presence, blending its rugged heritage with Genesco's footwear expertise. The first collection, featuring classic and trend-driven styles, will launch in Fall 2026.
'We are thrilled to partner with Genesco, an industry leader with a proven track record of successfully interpreting brands and bringing compelling footwear to market,' said Steve Armus, Vice President of Licensing and Collaborations at Wrangler . 'This licensing agreement represents a promising opportunity to introduce Wrangler footwear to a wide audience. We believe this partnership will strengthen our brand presence and allow more consumers to experience the quality and heritage of Wrangler in an exciting new product category.'
'Partnering with Wrangler presents a meaningful opportunity to accelerate growth in our Genesco Brands Group portfolio,' said Rick Higgins, President of Genesco Brands Group . 'We're excited to leverage our know-how to build a footwear assortment that honors Wrangler's legacy of adventure, new frontiers and craftsmanship. From everyday workwear to casual lifestyle to Western-inspired silhouettes, we see significant potential to blend rugged authenticity with unique styling, storytelling, innovation and comfort.'
The first Wrangler footwear collection under the licensing agreement is expected to launch in Fall 2026. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged.
Fibre2Fashion News Desk (RM)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
UK deal will set roadmap for talks with EU, but US a different ballgame: Sunil Bharti Mittal
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Bharti Enterprises chairman Sunil Bharti Mittal , who co-chairs the India-UK CEO Forum and is leading a 16-member industry delegation accompanying Prime minister Narendra Modi to London for signing the trade detail, tells Romit Guha and Deepshikha Sikarwar that it is time for Indian industry to step up its game in the UK. Edited excerpts:This is the first real pact signed between two large nations where the economies are of a similar size, $3.5 trillion. It is a Western world economy and has a number of technologies which are very useful right out. The Indian market is very important for UK companies and equally, India needs to step up its game in the so far the trade between the two countries was $56 billion, which makes it a fairly large trading partner, the ambition of both our Prime Ministers is to more than double this in less than five years. So, taking it to $120 billion dollars by 2030 is an ambitious have gained a three-year exemption on social security payments. I believe the estimates are about Rs 4,000 crore of savings for the Indian a win-win for both sides. I hope the investments will step up in India we don't have blockages like in the 70s and 80s when imports were restricted. Everything is open for imports. The question is really on tariffs. Tariffs between India and the UK were not that high. The UK is a sizable market with (a population of) 65 million. India is a continent of 1.5 billion people. This is the kind of market that any Western world would be happy to access on favourable terms. And this is what the UK gets. But in turn, what do they need to do? Set up more factories, more manufacturing in India, step up investments, maybe do some acquisitions, because in the UK, manufacturing is not as competitive as it is in India. Equally, there is a pool of talent available in India, in Indian companies, they can now come and acquire companies in the UK. There are a lot of gems sitting out here. They have been weak in their valuations because of low local demand. And now bridge it with India. And you're seeing TVS Motor coming and buying; we have come and made some investments here. Tata's Jaguar Land Rover is sending cars to India now. It will now become better for them to send at a lower duty. I would say this is a really well-crafted trade I would say the high-tech area, especially defence — hypersonic missiles, UAVs, drones, these technologies that are in the UK at a very advanced level. The UK is a very advanced Western defence manufacturing nation, whether it's fighter jets or UAVs. It has a lot of technology sitting here, which India will have access to now. We can expect deeper cooperation, different partnerships, including hopefully in the area of is SME, which is at the other end of the spectrum. We had leather, leather footwear, handicrafts and small hand tools, machine tools, and small automobile parts which are required in the UK. All these in India will now get access into the UK market on a preferential basis at very low or almost nil duties. We have also successfully protected certain sensitive sectors, for example has done quite a few FTAs — with the European Free Trade Association, Australia, the United Arab Emirates. The trade deal with the UK to my mind is the first big western one, and this will set the roadmap for talks with the European Union. I hope that in the coming weeks and months, the EU will start to take US is altogether a different ballgame. The Indian government is keenly negotiating various issues that are coming up there. It is not an easy task to have a free trade agreement or a comprehensive trade agreement with a large market like the US, which can not only take a lot of things from you, but also send a lot of things back into your country. So, one will have to take a balanced approach, a more nuanced approach. But I think there seems to be an urgency. But I think all these agreements, like the UK, will add to India's are in a new world. Even in the first term of Donald Trump, we could see multilateralism getting weakened. And, in the second term, much more of that. I don't know how much relevance the WTO will have. But it seems more and more, bilateralism is going to become fashionable.I have had the privilege of working on some back channels for this deal as well. Our investments in the UK help us have a voice on the table. We have big investments in the hospitality, real estate sectors, British Telecom, which is an iconic British company and, of course, OneWeb. We remain pretty agile in the UK market and we look for opportunities in growing our investments in key we are inside BT now. We are the single largest shareholder with 25%. My relationship with the chairman and CEO and some of the board members is outstanding. We work with them, we have given them a number of suggestions, which they like. They had visited India with a big delegation to see how we operate.I think there are lots of things that BT can pick up from Airtel in India. But, equally, we are also seeing some of the stuff that they are doing. For example, in open ridge, the way they do the trenching, the connections they have at homes. So, this is going to be a nice cooperation between the two companies where the bridge is Bharti Enterprises, which has a controlling stake in Airtel in India and an influential stake in BT.
News18
2 hours ago
- News18
'Challenges Don't Come from China' Xi Snaps Back as Eu Dubs Russia 'Determining Factor' for Ties
EU chief Ursula von der Leyen warned on Thursday that China's ties with Russia were now the "determining" factor in its relations with the European Union, as she wrapped up a tense summit in Beijing that also saw China agree to speed up exports of rare earth minerals to the says China's deepening political and economic relations with Moscow since the 2022 invasion have helped Russia's economy weather sweeping Western sanctions. Beijing denies that up that summit, von der Leyen told a news conference in Beijing that the bloc had made clear that the issue was now the "determining" factor in its relations with and European Council President Antonio Costa expressed "our expectations that China would follow up on our concerns and the expectation that it would use its influence to bring Russia to accept a ceasefire, to come to the negotiation table, enter peace talks and put an end to the bloodshed", von der Leyen said. n18oc_world n18oc_crux0:00 INTRODUCTION3:42 XI URGES EU TO MAKE 'CORRECT STRATEGIC CHOICES'4:50 CHINA MASKS RUSSIA DRONE ENGINES AS "INDUSTRIAL REFRIGERATION UNITS"
Economic Times
3 hours ago
- Economic Times
Federal heat on UnitedHealth sends shares tumbling — what you need to know
Synopsis UnitedHealth DOJ probe impacts stock value as federal heat intensifies on the healthcare giant. The U.S. Justice Department has launched both criminal and civil investigations into UnitedHealth's Medicare Advantage billing practices, raising serious concerns about possible overcharging. As news broke, UnitedHealth's stock plunged over 4%, deepening a year-long 40% decline. Investors are now worried about future earnings, rising healthcare costs, and tighter regulations. UnitedHealth says it's cooperating fully and reviewing its billing system. With leadership changes and legal pressure mounting, this story is a must-read for anyone watching the healthcare or stock market space right now. UnitedHealth Group (NYSE: UNH) stock has lost over 40% of its value in 2025, wiping out more than $120 billion in market capitalization. The latest blow came after the healthcare giant confirmed it is under criminal and civil investigation by the U.S. Department of Justice (DOJ) over its Medicare Advantage billing practices, sending shares tumbling nearly 4% in pre-market trading. With rising medical costs, shaken investor confidence, and leadership upheaval, UnitedHealth's dramatic decline marks one of the worst performances among S&P 500 stocks this year. UnitedHealth Group Inc. (NYSE: UNH) saw its stock tumble nearly 4% today, continuing a steep downward spiral that has erased over 40% of its value in 2025 alone. The latest drop comes after the company confirmed that it's under both criminal and civil investigation by the U.S. Department of Justice (DOJ), related to its Medicare Advantage billing practices. UnitedHealth stock has been among the worst performers on the S&P 500 this year. After starting 2025 near $525 per share, the stock has plummeted below $300, marking a more than 40% year-to-date drop. Key moments behind the plunge: April 2025 : Stock dropped 22% in a single day after missing Q1 earnings and slashing full-year guidance. : Stock dropped after missing Q1 earnings and slashing full-year guidance. May 2025 : CEO Andrew Witty resigned, adding leadership instability to the mix. : CEO Andrew Witty resigned, adding leadership instability to the mix. July 2025: Confirmation of DOJ investigation triggers renewed selling pressure. The Department of Justice (DOJ) is officially investigating UnitedHealth Group—America's largest health insurer—over its Medicare Advantage billing. The federal probes focus on whether the company artificially inflated patient risk scores to receive higher reimbursements from the government. UnitedHealth has confirmed receiving requests for information from the DOJ and stated it is cooperating fully with both criminal and civil investigations. While the company initially denied any criminal probe, it now admits it had proactively reached out to federal authorities earlier this year to clarify billing procedures and launch internal reviews. The DOJ's primary concern is centered on risk adjustment coding—a process that determines how much money the federal government pays insurers like UnitedHealth based on patients' medical conditions. Allegations suggest the company may have exaggerated diagnoses to collect excess payments from Medicare. As soon as news of the investigation surfaced, UnitedHealth stock took a hit. Shares fell over 4% in premarket trading, extending a broader decline that's seen the stock drop more than 40% year-to-date. This is not an isolated event. Earlier this year, UnitedHealth's stock experienced a major downturn when its former CEO unexpectedly resigned and the company withdrew its 2025 earnings guidance, citing cost overruns tied to its Medicare Advantage business. The current legal troubles are piling onto existing financial pressures, sending a clear message to investors: the road ahead may be rocky. At the heart of the investigation is Medicare Advantage, a privately managed health insurance program funded by the federal government. Insurers like UnitedHealth receive payments based on the health risk profiles of their enrollees. The more serious the health conditions of a patient, the higher the risk score—and the larger the government payout. However, the DOJ is now investigating whether UnitedHealth manipulated these scores by inflating patient diagnoses. This isn't a new concern in the industry. Other insurers have faced similar audits and lawsuits. However, given UnitedHealth's size and influence, the implications could be significantly larger. This is the big question facing investors. UNH stock may look cheap relative to historical valuation, but headline risk remains high. Here are two opposing scenarios: Bull Case: DOJ investigation ends with a manageable settlement. Medical cost inflation stabilizes. Leadership transition brings strategic clarity. Bear Case: Legal issues expand and trigger major fines or contract losses. Costs continue rising, forcing more earnings cuts. Institutional investors exit further, adding pressure. In response to the federal heat, UnitedHealth has taken several steps to present itself as compliant and transparent: Voluntary Disclosures : The company claims it initiated contact with the DOJ months ago and is cooperating with all requests. : The company claims it initiated contact with the DOJ months ago and is cooperating with all requests. Third-party Audits : UnitedHealth says it is conducting external reviews of its risk adjustment processes, possibly signaling internal reforms are underway. : UnitedHealth says it is conducting external reviews of its risk adjustment processes, possibly signaling internal reforms are underway. Compliance Enhancements: The insurer is working on strengthening its internal controls to ensure billing accuracy going forward. Despite these efforts, legal experts suggest that even if no wrongdoing is found, the very existence of a federal investigation could lead to increased regulatory oversight, reputational damage, and mounting legal expenses. The DOJ probe comes at a time when UnitedHealth is already navigating several internal and external challenges: In May, longtime CEO Andrew Witty stepped down unexpectedly amid the growing storm. Former CEO Stephen Hemsley returned to stabilize the company and restore investor trust. Healthcare utilization surged in recent quarters, leading to higher-than-expected medical costs. UnitedHealth has warned of increased pressure on margins due to greater demand for surgeries, outpatient care, and chronic condition treatments. Alongside regulatory attention, UnitedHealth is facing public scrutiny. If the DOJ finds grounds for prosecution, the company could face heavy fines, tighter compliance mandates, or even restrictions on future government contracts. For investors, the combination of legal risk, leadership uncertainty, and financial strain creates a complex risk profile. Shareholder Value : With shares down over 40% YTD, portfolio exposure is already taking a hit. : With shares down over 40% YTD, portfolio exposure is already taking a hit. Earnings Outlook : With the company pulling its 2025 forecast, investors are left without clarity on future earnings potential. : With the company pulling its 2025 forecast, investors are left without clarity on future earnings potential. Regulatory Uncertainty: Prolonged investigations may drag down sentiment and stock performance even if no wrongdoing is proven. While some see the current dip as a buying opportunity in a fundamentally strong company, others warn that further volatility is likely in the coming quarters. Earnings Report (Early August) : Investors are eagerly awaiting the next quarterly results. The focus will be on legal disclosures, medical cost trends, and updated guidance. : Investors are eagerly awaiting the next quarterly results. The focus will be on legal disclosures, medical cost trends, and updated guidance. DOJ Progress Updates : Any new details about the investigation's scope, possible subpoenas, or charges could further affect stock movement. : Any new details about the investigation's scope, possible subpoenas, or charges could further affect stock movement. Organizational Changes: Investors will also watch for more leadership reshuffles or board-level changes aimed at regaining market trust. The UnitedHealth DOJ investigation is a serious matter—not just for the company, but for the broader health insurance industry. While the company has made moves toward transparency and reform, the federal probe introduces significant uncertainty around both earnings and regulatory compliance. If you're an investor, this is a moment to remain informed and cautious. Watching how the company navigates the legal, financial, and reputational fallout will be critical in determining whether UnitedHealth can regain its footing—or if deeper troubles lie ahead. Q1: Why is UnitedHealth under DOJ investigation? The DOJ is probing UnitedHealth for possibly overbilling Medicare Advantage through inflated diagnoses. Q2: How did the DOJ probe affect UnitedHealth stock? UnitedHealth stock fell sharply after the DOJ launched its criminal and civil investigations.
